Mucin 1 expression is regulated by hsa_circ_0055054/microRNA‑122‑5p and promotes hepatocellular carcinoma development

Hao,Pengfei; Li,Qi; Zhao,Haoliang

doi:10.3892/ol.2024.14537

Mucin 1 expression is regulated by hsa_circ_0055054/microRNA‑122‑5p and promotes hepatocellular carcinoma development

Authors:
- Pengfei Hao
- Qi Li
- Haoliang Zhao
View Affiliations

Affiliations: Department of General Surgery, Third Hospital of Shanxi Medical University, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Tongji Shanxi Hospital, Taiyuan, Shanxi 030032, P.R. China, Department of General Surgery, Shanxi Provincial People's Hospital, Taiyuan, Shanxi 030001, P.R. China
Published online on: June 27, 2024 https://doi.org/10.3892/ol.2024.14537
Article Number: 404
Copyright: © Hao et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The abnormal expression of mucin 1 (MUC1) is a major cause of poor prognosis in patients with hepatocellular carcinoma (HCC). Competitive endogenous RNA demonstrates a novel regulatory mechanism that can affect the biological behavior of tumors. In the present study, the regulatory functions of hsa_circ_0055054 as well as those of microRNA (miR/miRNA) 122‑5p on MUC1 expression and its role in HCC cell proliferation, migration and invasion, were evaluated. MUC1 expression was assessed using western blotting and reverse transcription‑quantitative PCR. The phenotypic functions of the HCC cell lines were evaluated following MUC1 knockdown using Cell Counting Kit‑8, wound healing and Transwell assays. Bioinformatics tools were used to identify specific miRNAs and circular (circ)RNAs that interact with and can regulate MUC1. The stability of circRNAs was assessed using a Ribonuclease R assay. The binding of circRNA/miRNA/MUC1 was assessed using dual‑luciferase reporter assays and cellular function tests. Finally, in vivo experiments were performed using animal models. The results demonstrated that in MHCC97L cells, MUC1 and hsa_circ_0055054 were expressed at high levels while miR‑122‑5p was downregulated. The proliferation, migration and invasion of MHCC97L cells were suppressed by low MUC1 expression. hsa_circ_0055054 knockdown or miR‑122‑5p overexpression both led to a decrease in MUC1 expression. In MHCC97L cells with a low MUC1 expression caused by hsa_circ_0055054 knockdown, miR‑122‑5p inhibition resulted in the increased proliferation, migration and invasion of MHCC97L cells. In combination, the results of the present study indicate that hsa_circ_0055054 knockdown in MHCC97L cells leads to an increased expression of miR‑122‑5p and decreased expression of MUC1, which results in the inhibition of MHCC97L cell proliferation, migration and invasion.

View Figures

View References

1	Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A and Bray F: Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 71:209–249. 2021. View Article : Google Scholar : PubMed/NCBI
2	Farazi PA and DePinho RA: Hepatocellular carcinoma pathogenesis: From genes to environment. Nat Rev Cancer. 6:674–687. 2006. View Article : Google Scholar : PubMed/NCBI
3	Junttila MR and de Sauvage FJ: Influence of tumour micro- environment heterogeneity on therapeutic response. Nature. 501:346–354. 2013. View Article : Google Scholar : PubMed/NCBI
4	Quail DF and Joyce JA: Microenvironmental regulation of tumor progression and metastasis. Nat Med. 19:1423–1437. 2013. View Article : Google Scholar : PubMed/NCBI
5	Ringel J and Löhr M: The MUC gene family: Their role in diagnosis and early detection of pancreatic cancer. Mol Cancer. 2:92003. View Article : Google Scholar : PubMed/NCBI
6	Bhatia R, Gautam SK, Cannon A, Thompson C, Hall BR, Aithal A, Banerjee K, Jain M, Solheim JC, Kumar S and Batra SK: Cancer-associated mucins: Role in immune modulation and metastasis. Cancer Metastasis Rev. 38:223–236. 2019. View Article : Google Scholar : PubMed/NCBI
7	Li W, Han Y, Sun C, Li X, Zheng J, Che J, Yao X and Kufe D: Novel insights into the roles and therapeutic implications of MUC1 oncoprotein via regulating proteins and non-coding RNAs in cancer. Theranostics. 12:999–1011. 2022. View Article : Google Scholar : PubMed/NCBI
8	Nabavinia MS, Gholoobi A, Charbgoo F, Nabavinia M, Ramezani M and Abnous K: Anti-MUC1 aptamer: A potential opportunity for cancer treatment. Med Res Rev. 37:1518–1539. 2017. View Article : Google Scholar : PubMed/NCBI
9	Ren J, Agata N, Chen D, Li Y, Yu WH, Huang L, Raina D, Chen W, Kharbanda S and Kufe D: Human MUC1 carcinoma-associated protein confers resistance to genotoxic anticancer agents. Cancer Cell. 5:163–175. 2004. View Article : Google Scholar : PubMed/NCBI
10	Nath S and Mukherjee P: MUC1: A multifaceted oncoprotein with a key role in cancer progression. Trends Mol Med. 20:332–342. 2014. View Article : Google Scholar : PubMed/NCBI
11	Ye J, Wei X, Shang Y, Pan Q, Yang M, Tian Y, He Y, Peng Z, Chen L, Chen W and Wang R: Core 3 mucin-type O-glycan restoration in colorectal cancer cells promotes MUC1/p53/miR-200c-dependent epithelial identity. Oncogene. 36:6391–6407. 2017. View Article : Google Scholar : PubMed/NCBI
12	Roy LD, Sahraei M, Subramani DB, Besmer D, Nath S, Tinder TL, Bajaj E, Shanmugam K, Lee YY, Hwang SI, et al: MUC1 enhances invasiveness of pancreatic cancer cells by inducing epithelial to mesenchymal transition. Oncogene. 30:1449–1459. 2011. View Article : Google Scholar : PubMed/NCBI
13	Yuan SF, Li KZ, Wang L, Dou KF, Yan Z, Han W and Zhang YQ: Expression of MUC1 and its significance in hepatocellular and cholangiocarcinoma tissue. World J Gastroenterol. 11:4661–4666. 2005. View Article : Google Scholar : PubMed/NCBI
14	Liu L, Gu M, Ma J, Wang Y, Li M, Wang H, Yin X and Li X: CircGPR137B/miR-4739/FTO feedback loop suppresses tumorigenesis and metastasis of hepatocellular carcinoma. Mol Cancer. 21:1492022. View Article : Google Scholar : PubMed/NCBI
15	Liu W, Zheng L, Zhang R, Hou P, Wang J, Wu L and Li J: Circ-ZEB1 promotes PIK3CA expression by silencing miR-199a-3p and affects the proliferation and apoptosis of hepatocellular carcinoma. Mol Cancer. 21:722022. View Article : Google Scholar : PubMed/NCBI
16	Yu J, Xu QG, Wang ZG, Yang Y, Zhang L, Ma JZ, Sun SH, Yang F and Zhou WP: Circular RNA cSMARCA5 inhibits growth and metastasis in hepatocellular carcinoma. J Hepatol. 68:1214–1227. 2018. View Article : Google Scholar : PubMed/NCBI
17	Zhou WY, Cai ZR, Liu J, Wang DS, Ju HQ and Xu RH: Circular RNA: Metabolism, functions and interactions with proteins. Mol Cancer. 19:1722020. View Article : Google Scholar : PubMed/NCBI
18	Ni J, Bucci J, Chang L, Malouf D, Graham P and Li Y: Targeting MicroRNAs in prostate cancer radiotherapy. Theranostics. 7:3243–3259. 2017. View Article : Google Scholar : PubMed/NCBI
19	Han B, Chao J and Yao H: Circular RNA and its mechanisms in disease: From the bench to the clinic. Pharmacol Ther. 187:31–44. 2018. View Article : Google Scholar : PubMed/NCBI
20	Kristensen LS, Jakobsen T, Hager H and Kjems J: The emerging roles of circRNAs in cancer and oncology. Nat Rev Clin Oncol. 19:188–206. 2022. View Article : Google Scholar : PubMed/NCBI
21	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
22	Patel KN, Maghami E, Wreesmann VB, Shaha AR, Shah JP, Ghossein R and Singh B: MUC1 plays a role in tumor maintenance in aggressive thyroid carcinomas. Surgery. 138:994–1002. 2005. View Article : Google Scholar : PubMed/NCBI
23	Lucarelli G, Netti GS, Rutigliano M, Lasorsa F, Loizzo D, Milella M, Schirinzi A, Fontana A, Di Serio F, Tamma R, et al: MUC1 expression affects the immunoflogosis in renal cell carcinoma microenvironment through complement system activation and immune infiltrate modulation. Int J Mol Sci. 24:48142023. View Article : Google Scholar : PubMed/NCBI
24	Schroeder JA, Adriance MC, Thompson MC, Camenisch TD and Gendler SJ: MUC1 alters beta-catenin-dependent tumor formation and promotes cellular invasion. Oncogene. 22:1324–1332. 2003. View Article : Google Scholar : PubMed/NCBI
25	Yuan H, Wang J, Wang F, Zhang N, Li Q, Xie F, Chen T, Zhai R, Wang F, Guo Y, et al: Mucin 1 gene silencing inhibits the growth of SMMC-7721 human hepatoma cells through Bax-mediated mitochondrial and caspase-8-mediated death receptor apoptotic pathways. Mol Med Rep. 12:6782–6788. 2015. View Article : Google Scholar : PubMed/NCBI
26	Bose M and Mukherjee P: Microbe-MUC1 crosstalk in cancer-associated infections. Trends Mol Med. 26:324–336. 2020. View Article : Google Scholar : PubMed/NCBI
27	Wang J, Ni WH, Hu KB, Zhai XY, Xie F, Jie J, Zhang NN, Jiang LN, Yuan HY and Tai GX: Targeting MUC1 and JNK by RNA interference and inhibitor inhibit the development of hepatocellular carcinoma. Cancer Sci. 108:504–511. 2017. View Article : Google Scholar : PubMed/NCBI
28	Bozkaya G, Korhan P, Cokaklı M, Erdal E, Sağol O, Karademir S, Korch C and Atabey N: Cooperative interaction of MUC1 with the HGF/c-Met pathway during hepatocarcinogenesis. Mol Cancer. 11:642012. View Article : Google Scholar : PubMed/NCBI
29	Apostolopoulos V, Stojanovska L and Gargosky SE: MUC1 (CD227): A multi-tasked molecule. Cell Mol Life Sci. 72:4475–4500. 2015. View Article : Google Scholar : PubMed/NCBI
30	Carson DD: The cytoplasmic tail of MUC1: A very busy place. Sci Signal. 1:pe352008. View Article : Google Scholar : PubMed/NCBI
31	Supruniuk K and Radziejewska I: MUC1 is an oncoprotein with a significant role in apoptosis (review). Int J Oncol. 59:682021. View Article : Google Scholar : PubMed/NCBI
32	Villanueva L, Álvarez-Errico D and Esteller M: The contribution of epigenetics to cancer immunotherapy. Trends Immunol. 41:676–691. 2020. View Article : Google Scholar : PubMed/NCBI
33	Winkle M, El-Daly SM, Fabbri M and Calin GA: Noncoding RNA therapeutics-challenges and potential solutions. Nat Rev Drug Discov. 20:629–651. 2021. View Article : Google Scholar : PubMed/NCBI
34	Wang N, Zheng J, Chen Z, Liu Y, Dura B, Kwak M, Xavier-Ferrucio J, Lu YC, Zhang M, Roden C, et al: Single-cell microRNA-mRNA co-sequencing reveals non-genetic heterogeneity and mechanisms of microRNA regulation. Nat Commun. 10:952019. View Article : Google Scholar : PubMed/NCBI
35	Wang L, Zhang Z and Wang FS: The efficacy of miRNA122, a novel therapeutic target, for predicting the progression of hepatocellular carcinoma (HCC). Cell Mol Immunol. 9:103–104. 2012. View Article : Google Scholar : PubMed/NCBI
36	Bandiera S, Pfeffer S, Baumert TF and Zeisel MB: miR-122-a key factor and therapeutic target in liver disease. J Hepatol. 62:448–457. 2015. View Article : Google Scholar : PubMed/NCBI
37	Nakao K, Miyaaki H and Ichikawa T: Antitumor function of microRNA-122 against hepatocellular carcinoma. J Gastroenterol. 49:589–593. 2014. View Article : Google Scholar : PubMed/NCBI
38	Xu Y, Xia F, Ma L, Shan J, Shen J, Yang Z, Liu J, Cui Y, Bian X, Bie P and Qian C: MicroRNA-122 sensitizes HCC cancer cells to adriamycin and vincristine through modulating expression of MDR and inducing cell cycle arrest. Cancer Lett. 310:160–169. 2011.PubMed/NCBI
39	Luna JM, Barajas JM, Teng KY, Sun HL, Moore MJ, Rice CM, Darnell RB and Ghoshal K: Argonaute CLIP defines a deregulated miR-122-bound transcriptome that correlates with patient survival in human liver cancer. Mol Cell. 67:400–410.e7. 2017. View Article : Google Scholar : PubMed/NCBI
40	Chen S, Zhang Y, Ding X and Li W: Identification of lncRNA/circRNA-miRNA-mRNA ceRNA network as biomarkers for hepatocellular carcinoma. Front Genet. 13:8388692022. View Article : Google Scholar : PubMed/NCBI
41	Singh D, Kesharwani P, Alhakamy NA and Siddique HR: Accentuating CircRNA-miRNA-transcription factors axis: A conundrum in cancer research. Front Pharmacol. 12:7848012022. View Article : Google Scholar : PubMed/NCBI
42	Xiong DD, Dang YW, Lin P, Wen DY, He RQ, Luo DZ, Feng ZB and Chen G: A circRNA-miRNA-mRNA network identification for exploring underlying pathogenesis and therapy strategy of hepatocellular carcinoma. J Transl Med. 16:2202018. View Article : Google Scholar : PubMed/NCBI
43	Li D, Guan M, Cao X, Zha ZQ, Zhang P, Xiang H, Zhou Y, Peng Q, Xu Z, Lu L and Liu G: GFPT1 promotes the proliferation of cervical cancer via regulating the ubiquitination and degradation of PTEN. Carcinogenesis. 43:969–979. 2022. View Article : Google Scholar : PubMed/NCBI
44	Gong Y, Qian Y, Luo G, Liu Y, Wang R, Deng S, Cheng H, Jin K, Ni Q, Yu X, et al: High GFPT1 expression predicts unfavorable outcomes in patients with resectable pancreatic ductal adenocarcinoma. World J Surg Oncol. 19:352021. View Article : Google Scholar : PubMed/NCBI
45	Zhang C, Lian H, Xie L, Yin N and Cui Y: LncRNA ELFN1-AS1 promotes esophageal cancer progression by up-regulating GFPT1 via sponging miR-183-3p. Biol Chem. 401:1053–1061. 2020. View Article : Google Scholar : PubMed/NCBI